All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mGC or mGEJC - 1st line (L1), pembrolizumab alone vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.91 [0.75; 1.11]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.69 [0.49; 0.97]
0.82 [0.63 ; 1.07 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 2 47% 688 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 1.66 [1.37; 2.01]
KEYNOTE-062 (P vs C ; CPS>10), 2020 1.10 [0.80; 1.52]
1.38 [0.92 ; 2.06 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 2 78% 688 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.29 [0.19; 0.45]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.55 [0.29; 1.04]
0.38 [0.21 ; 0.70 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 2 61% 688 moderate not evaluable AE (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.34 [0.11; 1.06]
0.34 [0.11 ; 1.06 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.06; 0.14]
0.09 [0.06 ; 0.14 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.19 [0.09; 0.38]
0.19 [0.09 ; 0.38 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable TRAE (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.11 [0.06; 0.18]
0.11 [0.06 ; 0.18 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.10 [0.03; 0.27]
0.10 [0.03 ; 0.27 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.01; 0.73]
0.09 [0.01 ; 0.73 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.06; 15.44]
0.96 [0.06 ; 15.44 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.16 [0.05; 0.55]
0.16 [0.05 ; 0.55 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.20 [0.06; 0.69]
0.20 [0.06 ; 0.69 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.01; 0.50]
0.06 [0.01 ; 0.50 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 1.92 [0.06; 57.64]
1.92 [0.06 ; 57.64 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.51]
0.03 [0.00 ; 0.51 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.01; 0.37]
0.05 [0.01 ; 0.37 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale KEYNOTE-062 (P vs C ; CPS>1), 2020 0.01 [0.00; 0.08]
0.01 [0.00 ; 0.08 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.00; 1.02]
0.06 [0.00 ; 1.02 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.24 [0.01; 5.32]
0.24 [0.01 ; 5.32 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.00; 0.89]
0.05 [0.00 ; 0.89 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.55]
0.03 [0.00 ; 0.55 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 21:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 122,271,262,260,219,184
- treatments: 359,575,577,576,869